Clinical trial
A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen
NCT00135343 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00135343 |
|---|---|
| Title | A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen |
| Official title | A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Atazanvir/ritonavir + efavirenz |
| Enrollment | 60 |
| Start date | Apr 1, 2004 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Aug 26, 2005 |
| Last update posted | Apr 14, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: